<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492283</url>
  </required_header>
  <id_info>
    <org_study_id>LINK-1-2011</org_study_id>
    <secondary_id>H-1-2011-082</secondary_id>
    <nct_id>NCT01492283</nct_id>
  </id_info>
  <brief_title>Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes</brief_title>
  <official_title>Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to analyze the pathophysiological implications of
      glucagon and the incretin hormones in patients with liver disease (Non alcoholic fatty liver
      disease (NAFLD) or cirrhosis) with and without diabetes compared with healthy controls. The
      present study will contribute significantly to the understanding of the pathophysiology of
      liver disease and glucose metabolism. The final goal is that the results could pave the way
      for new treatment modalities for patients with liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of of insulin secretion (Area Under the Curve (AUC)) during the experimental days.
      Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose
      levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Incretin effect</measure>
    <time_frame>pre dose 0,10, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 240 min post dose</time_frame>
    <description>The difference in insulin responses, as assessed by the area under curve (AUC) for plasma insulin and C-peptide concentrations, during the two different glucose stimuli: Oral glucose tolerance test (OGTT) and isoglycemic iv glucose infusion in NAFLD patients with and without diabetes, and cirrhotic patients compared to healthy control subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucagon like peptide 1 (GLP-1) response</measure>
    <time_frame>pre dose 0,10, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 240 min post dose</time_frame>
    <description>Comparing GLP-1 responses of the different experimental days, compared to healthy control subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose-dependent insulinotropic peptide (GIP) response</measure>
    <time_frame>pre dose 0,10, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 240 min post dose</time_frame>
    <description>Comparing GIP responses of the different experimental days, compared to healthy control subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucagon response</measure>
    <time_frame>pre dose 0,10, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 240 min post dose</time_frame>
    <description>Comparing glucagon responses of the different experimental days, compared to healthy control subjects.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>NAFLD</arm_group_label>
    <description>Non alcoholic fatty liver disease without type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD+T2D</arm_group_label>
    <description>Non alcoholic fatty liver disease with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D</arm_group_label>
    <description>Type 2 diabetics without non alcoholic fatty liver disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cirrhosis</arm_group_label>
    <description>Patients with liver cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kontrol groups</arm_group_label>
    <description>Healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OGTT</intervention_name>
    <description>50g waterfree glucose dissolved in 300 ml water consumed over 5 min.</description>
    <arm_group_label>NAFLD</arm_group_label>
    <arm_group_label>NAFLD+T2D</arm_group_label>
    <arm_group_label>T2D</arm_group_label>
    <arm_group_label>cirrhosis</arm_group_label>
    <arm_group_label>Kontrol groups</arm_group_label>
    <other_name>Waterfree glucose, The Pharmacy of the capital region</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IIGI</intervention_name>
    <description>iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose</description>
    <arm_group_label>NAFLD</arm_group_label>
    <arm_group_label>NAFLD+T2D</arm_group_label>
    <arm_group_label>T2D</arm_group_label>
    <arm_group_label>cirrhosis</arm_group_label>
    <arm_group_label>Kontrol groups</arm_group_label>
    <other_name>Glucose infusion, 20%</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA (whole blood) will be kept for 15 years
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with NAFLD and liver cirrhosis confirmed by liver biopsy, and patients with or
        without well characterized type 2 diabetes recruited in the the hospitals out patients
        clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        I) Group 1: NAFLD patients with normal glucose tolerance Inclusion criteria

          -  NAFLD verified by a liver biopsy

          -  Caucasian &gt;18 years of age

          -  Negative islet cell (ICA) and glutamic acid decarboxylase 65 (GAD65) autoantibodies

          -  Normal 75-g OGTT as specified in the WHO Criteria

          -  Normal haemoglobin and blood pressure (BP)

          -  Written informed consent

        II) Group 2: NAFLD patients with type 2 diabetes Inclusion criteria

          -  NAFLD verified by liver biopsy

          -  T2DM according to the WHO Criteria

          -  Caucasian &gt;18 years of age

          -  Negative ICA and GAD65, normal haemoglobin, normal BP

          -  Written informed consent

        III) Group 3: NAFLD patients without type 2 diabetes Inclusion criteria

          -  NAFLD verified by liver biopsy

          -  Caucasian &gt;18 years of age

          -  Normal 75-g OGTT

          -  Negative ICA and GAD65-autoantibodies

          -  Normal haemoglobin and BP

          -  Written informed consent

        IV) Group 4: Cirrhosis with or without type 2 diabetes Inclusion criteria

          -  Liver cirrhosis verified by liver biopsy

          -  Caucasian &gt; 18 years of age

          -  Negative ICA and GAD65-autoantibodies

          -  Normal haemoglobin and BP

          -  Written informed consent

        V) Group 5: Healthy controls Inclusion criteria

          -  Caucasian &gt;18 years of age

          -  Normal 75-g OGTT according to the WHO Criteria

          -  Negative ICA and GAD65-autoantibodies

          -  Normal haemoglobin and BP

          -  Written informed consent

        Exclusion criteria (all groups)

          -  Other known liver disease - viral hepatitis, hereditary haemochromatosis, autoimmune
             liver disease, alpha-1 trypsin deficiency, Wilson disease, drug induced liver Injury
             (DILI)

          -  Treatment with medications that cannot be discontinued for 12 hours

          -  Unwillingness to participate in protocols

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders E Junker, MD, phd-student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Division, Gentofte Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Division, Gentofte University Hospital, Niels Andersens Vej 65, opgang 4b, 1. sal</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Jonatan I Bagger</investigator_full_name>
    <investigator_title>MD PhD-student</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>Incretin hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

